Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JBI-802 |
| Synonyms | |
| Therapy Description |
JBI-802 inhibits KDM1A (LSD1) and HDAC6, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2022;82(23 Suppl_2):Abstract nr B029). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JBI-802 | JBI802|JBI 802 | HDAC Inhibitor 45 KDM1A Inhibitor 15 | JBI-802 inhibits KDM1A (LSD1) and HDAC6, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2022;82(23 Suppl_2):Abstract nr B029). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07207395 | Phase II | JBI-802 JBI-802 + Pembrolizumab | A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. | Recruiting | USA | 0 |
| NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |